Warren keeps pressure on pharma, this time targeting Amgen and Indivior buyouts

If you thought the passage of the Inflation Reduction Act might prompt Democrats to ease off the pharmaceutical industry, think again.

Late last week, Massachusetts Sen. Elizabeth Warren called on the Federal Trade Commission (FTC) to put a magnifying glass on a pair of pending Big Pharma mergers. Those are: Amgen’s buyout of rare disease drugmaker Horizon Therapeutics plus Indivior’s acquisition of Opiant and its nasal opioid overdose portfolio.